Schneider Eugene 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Eugene Schneider Receives Award and Sells Shares
What Happened
Eugene Schneider, EVP and Chief Clinical Development Officer at Ionis Pharmaceuticals (IONS), had 11,991 performance-based restricted stock units (PRSUs) vest on Jan 29, 2026 (reported as an award). The next day (Jan 30, 2026) he sold 6,179 shares in open-market transactions at a weighted-average price of $83.45, generating approximately $515,630 in proceeds. The award entry shows $0 acquisition price because these were vested PRSUs (not a cash purchase).
Key Details
- Transactions: Award/vesting of 11,991 shares (2026-01-29); open-market sale of 6,179 shares (2026-01-30).
- Sale price: weighted average $83.45 per share (individual sale prices ranged $83.32–$83.48). Proceeds ≈ $515,630.
- Net change from these transactions: +5,812 shares (11,991 vested − 6,179 sold). Total shares owned after the transactions are not provided in the excerpt.
- Footnote highlights: The vested PRSUs were from a Jan 18, 2023 grant and vested at 167.27% of target based on relative total shareholder return vs. peers (payout range 0%–200%). The filer can provide a breakdown of shares sold at each price within the stated range on request.
- Filing timeliness: Form filed 2026-02-02 for transactions on Jan 29–30, 2026; this filing is within normal Section 16 reporting timing.
Context
- These transactions reflect vesting of performance-based equity and a subsequent open-market sale of a portion of the vested shares. Awards/vests are compensation events; subsequent sales are commonly used to cover taxes or diversify and do not, by themselves, indicate management sentiment.
Insider Transaction Report
Form 4
Schneider Eugene
EVP, Chf Clinical Develop Ofcr
Transactions
- Award
Common Stock
[F1]2026-01-29+11,991→ 75,881 total - Sale
Common Stock
[F2]2026-01-30$83.45/sh−6,179$515,630→ 69,702 total
Footnotes (2)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.32 to $83.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider|2026-02-02